摘要
目的分析缬沙坦治疗慢阻肺并肺动脉高压的疗效。方法选择我院就诊的100例慢阻肺并肺动脉高压患者,随机分为试验组50例和对照组50例,对照组患者采用氧疗、化痰、平喘、抗感染、维持水电解质平衡等对症支持治疗,试验组则联合口服缬沙坦治疗。观察两组患者的肺动脉压改善效果,治疗前后肺功能指标、血气分析指标、肺部症状积分改善情况和用药不良反应情况。结果两组患者治疗前肺动脉收缩压、肺动脉平均压和肺动脉舒张压数据无显著差异(P>0.05),治疗后均显著下降(P<0.05),且试验组患者的肺动脉压下降水平低于对照组(P<0.05),两组患者治疗前相关肺功能指标比较,无统计学差异(P>0.05),治疗后均升高(P<0.05),且试验组的升高水平高于对照组(P<0.05),两组患者治疗前临床症状积分比较无明显差异(P>0.05),治疗后两组患者临床症状积分均明显改善(P<0.05),且试验组改善情况明显优于对照组(P<0.05),两组患者治疗期间未出现其他不良反应。结论缬沙坦治疗慢性肺并肺动脉高压的疗效显著,且用药安全,适合临床长期推广应用。
Objective To analyze the effect of valsartan in the treatment of chronic obstructive pulmonary disease with pulmonary hypertension. Methods 100 COPD patients complicated with pulmonary hypertension were selected from July 2012 to June 2015, and they were randomly divided into the experimental group and the control group, 50 cases in each group. The control group was treated with oxygen therapy, phlegm, asthma, anti-infection, maintaining water and electrolyte balance, while the experimental group was additionally treated with valsartan. The effect of pulmonary arterial pressure, pulmonary function indexes, blood gas analysis indexes, lung symptom score and and adverse drug reaction conditions were compared between the two groups. Results There was no significant difference in systolic and diastolic pulmonary arterial pressure between the two groups before treatment （ P 〉 0.05 ）. After treatment, systolic and diastolic pulmonary arterial pressure decreased significantly （ P 〈 0. 05）. The blood pressure level in the experimental group was significantly lower than that in the control group （ P 〈 0. 05 ）. There was no significant difference in the correlation index between the two groups before treatment （ P 〉 0. 05 ）. After treatment, the lung symptom score of the two groups were improved （ P 〈 0. 05 ）, and the improvement was more pronounced in the experimental group than in the control group （P 〈 0. 05 ）. Conclusion Valsartan has a significant curative effeet and no significant effect on renal function in the treatment of chronic obstructive pulmonary disease with pulmonary hypertension.
出处
《临床肺科杂志》
2016年第7期1239-1241,共3页
Journal of Clinical Pulmonary Medicine
